388 results
Page 2 of 20
424B5
a74k0n0nx 7vsvno
3 May 23
Prospectus supplement for primary offering
4:05pm
8-K
EX-10.1
h96 g9oh4
2 May 23
Entry into a Material Definitive Agreement
5:01pm
8-K
EX-3.1
lbfikmzi6utlt6yrnenu
2 May 23
Entry into a Material Definitive Agreement
5:01pm
8-K
EX-99.1
h4qtt
16 Feb 22
ImmunoGen Announces a Global, Multi-Target License Agreement of its Novel Camptothecin ADC Platform to Lilly for Up to $1.7 Billion
4:53pm
8-K
EX-1.1
phgmrn2
3 Dec 21
Entry into a Material Definitive Agreement
4:07pm
424B5
gi57xu3x7 u3bpt
3 Dec 21
Prospectus supplement for primary offering
4:06pm
424B5
2vxvcx1 blfkp7v
30 Nov 21
Prospectus supplement for primary offering
5:12pm
8-K
EX-99.1
pcutjxui
30 Nov 21
ImmunoGen Announces Positive Top-Line Results from Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer
6:37am
8-K
EX-99.1
2709pgon7ew m5abbs
29 Oct 21
ImmunoGen Reports Recent Progress and Third Quarter 2021 Financial Results
6:43am
8-K
1jdven
12 Aug 21
Entry into a Material Definitive Agreement
10:14am